Literature DB >> 10398438

The BRCA2 transactivation domain does not interact with JNK.

G H May1, F Harris, D Gillespie, D M Black.   

Abstract

The N-terminal region of BRCA2 has the capacity to activate transcription when fused to a heterologous DNA binding domain and includes a segment with amino acid similarity to the JNK-docking site in the cellular JUN protein. However, unlike JUN, we have determined that this region of BRCA2 neither interacts with nor serves as a substrate for JNK, or any other kinase that can be detected in extracts from either fibroblasts or epithelial cells. While this clearly does not rule out a transcriptional role for BRCA2, our findings indicate that BRCA2 is not regulated by the JNK pathway in a manner analogous to JUN. Genes Chromosomes Cancer 25:407-409, 1999. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10398438     DOI: 10.1002/(sici)1098-2264(199908)25:4<407::aid-gcc16>3.0.co;2-i

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  4 in total

Review 1.  Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases.

Authors:  Marie A Bogoyevitch; Bostjan Kobe
Journal:  Microbiol Mol Biol Rev       Date:  2006-12       Impact factor: 11.056

2.  A new c-Jun N-terminal kinase (JNK)-interacting protein, Sab (SH3BP5), associates with mitochondria.

Authors:  Carolyn Wiltshire; Masato Matsushita; Satoshi Tsukada; David A F Gillespie; Gerhard H W May
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

3.  An entire exon 3 germ-line rearrangement in the BRCA2 gene: pathogenic relevance of exon 3 deletion in breast cancer predisposition.

Authors:  Danièle Muller; Etienne Rouleau; Inès Schultz; Sandrine Caputo; Cédrick Lefol; Ivan Bièche; Olivier Caron; Catherine Noguès; Jean Marc Limacher; Liliane Demange; Rosette Lidereau; Jean Pierre Fricker; Joseph Abecassis
Journal:  BMC Med Genet       Date:  2011-09-22       Impact factor: 2.103

4.  Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovarian cancer.

Authors:  Sandrine M Caputo; Mélanie Léone; Francesca Damiola; Asa Ehlen; Aura Carreira; Pascaline Gaidrat; Alexandra Martins; Rita D Brandão; Ana Peixoto; Ana Vega; Claude Houdayer; Capucine Delnatte; Myriam Bronner; Danièle Muller; Laurent Castera; Marine Guillaud-Bataille; Inge Søkilde; Nancy Uhrhammer; Sophie Demontety; Hélène Tubeuf; Gaïa Castelain; Uffe Birk Jensen; Ambre Petitalot; Sophie Krieger; Cédrick Lefol; Virginie Moncoutier; Nadia Boutry-Kryza; Henriette Roed Nielsen; Olga Sinilnikova; Dominique Stoppa-Lyonnet; Amanda B Spurdle; Manuel R Teixeira; Florence Coulet; Mads Thomassen; Etienne Rouleau
Journal:  Oncotarget       Date:  2018-04-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.